tive Cases," by P. Hudson, M.D., M. Barringer, AB, and A. J. McBay, Ph. D., from Southern Medical Journal, vol. 70, No. 8, August 1977Letter dated November 30, 1976, to Administrator, Drug Enforcement Administration, Department of Justice, from Page Hudson, M.D., chief	Page 16659
medical examiner, and Arthur J. McBay, Ph. D., chief toxicologist Fact sheet, "Compliance and Regulatory Affairs," from the Drug Enforce-	16676
ment Administration, U.S. Department of Justice, December 1978 Fact sheet, "The Diversion Investigation Unit Program," Drug Enforce-	16722
ment Administration, U.S. Department of Justice, December 1978 Fact sheet, "DAWN (Drug Abuse Warning Network)." Drug Enforce-	16726
ment Administration, U.S. Department of Justice, December 1978 Article, "The Controlled Substances Act—Schedules of Controlled Substances," Drug Enforcement Administration, U.S. Department of	16730
stances," Drug Enforcement Administration, U.S. Department of Justice, December 1977. Article, "Fatalities Due to Propoxyphene," from the FDA Drug Bulletin,	16733
vol. 9, No. 1, February-March 1979. Article, "The Comprehensive Approach to Patient Care—Section 5—The Placebo Response," by L. A. Morris, Ph. D., and A. K. Shapiro, M.D.,	16826
Practice of Medicine, vol. X, ch. 32, 1977	16832
Change, 1978, pp. 369-410	16840
president, Corporate Medical Affairs, Eli Lilly & Co Letter dated January 18, 1979, to Sidney M. Wolfe, M.D., Health Research Group, from Vincent J. M. DiMaio, M.D., Institute of Forensic	16895
Sciences	17002
APPENDIX	
Statement of Hon. Joseph A. Califano, Jr., Secretary of Health, Education, Welfare, February 15, 1979Order of the Secretary denying petition, in re petition to suspend new	17004
drug applications for propoxyphene, U.S. Department of Health, Education, and Welfare, February 15, 1979 Article, "A Company at War: How Lilly Defended Darvon—Marshaling Forces in 'Red Flag Alert'," by Peter T. Kilborn, from the New York	17006
Letter dated January 22, 1979, to Senator Gaylord Nelson, chairman,	17012
Senate Small Business Committee, from Vernon McKenzie, Principal Deputy Assistant Secretary, U.S. Department of DefenseLetter dated January 24, 1979, to William Q. Sturner, M.D., chief medical examiner of Rhode Island, from Bryan S. Finkle, Ph. D., director,	17019
Center for Human Toxicology, University of Utah, plus summary of Darvon-related deaths in Rhode Island, 1974–78 (submitted at request of committee staff)	17021
of committee staff) Letter dated January 26, 1979, to Senator Gaylord Nelson, chairman, Senate Small Business Committee, from James G. Price, M.D., associate professor, Department of Family Practice, Kansas University	11021
Medical Center Letter dated January 31, 1979, to Senator Lowell P. Weicker, Jr., Senate Small Business Committee, from Norman R. and Shirley I. Toffolon,	17041
Farmington, ConnLetters dated January 26 and 30, 1979, to Senator Gaylord Nelson, chairman, Senate Small Business Committee, from Edgar G. Davis, vice	17043
president, corporate affairs, Eli Lilly & Co	17044 17082
president, corporate affairs, Eli Lilly & Co	17044 17082
president, corporate affairs, Eli Lilly & Co	17044 17082 16557
president, corporate affairs, Eli Lilly & Co	17082